Data Insights

EBBH-2024 by Essen Biotech for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Data Insights

Tumor Infiltrating Lymphocytes (TIL) by Essen Biotech for Metastatic Breast Cancer: Likelihood of Approval

Tumor Infiltrating Lymphocytes (TIL) is under clinical development by Essen Biotech and currently in Phase II for Metastatic Breast Cancer....

Data Insights

EBBH-2026 by Essen Biotech for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

EBBH-2026 is under clinical development by Essen Biotech and currently in Phase II for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute...

Data Insights

EBBH-2024 by Essen Biotech for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...

Data Insights

BH-002 by Essen Biotech for Rheumatoid Arthritis: Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Rheumatoid Arthritis

Data Insights

BH-002 by Essen Biotech for Systemic Lupus Erythematosus: Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Systemic Lupus Erythematosus

Data Insights

BH-002 by Essen Biotech for Systemic Sclerosis (Scleroderma): Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Systemic Sclerosis (Scleroderma)

Data Insights

BH-002 by Essen Biotech for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)

Data Insights

BH-002 by Essen Biotech for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)

Data Insights

BH-002 by Essen Biotech for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Idiopathic Inflammatory Myopathy (IIM)

Data Insights

BH-002 by Essen Biotech for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Data Insights

BH-002 by Essen Biotech for Primary Sjogren's Syndrome: Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Primary Sjogren's Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Primary Sjogren's Syndrome

Data Insights

BH-002 by Essen Biotech for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval

BH-002 is under clinical development by Essen Biotech and currently in Phase II for Immunoglobulin G4-Related Disease (IgG4-RD). According to...

Likelihood of Approval and Phase Transition Success Rate Model - BH-002 in Immunoglobulin G4-Related Disease (IgG4-RD)